A Phase 1, Open-label, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD489 and EFFEXOR XR, Administered Alone and in Combination in Healthy Adult Subjects

Shire1 个研究点分布在 1 个国家目标入组 80 人开始时间: 2010年10月28日最近更新: 2021年6月14日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Shire
入组人数: 80
试验地点: 1
主要终点: Cmax of d-Amphetamine

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study will examine the effects of co-administration of SPD489 and the antidepressant EFFEXOR XR on the pharmacokinetics of lisdexamfetamine, d-amphetamine, and EFFEXOR XR. In addition, serial blood pressure and pulse measures will be obtained and examined to ensure that there are no unexpected changes in vital signs following co administration of SPD489 and EFFEXOR XR that would impact the further study of this drug combination. The hypothesis is that a drug drug interaction could possibly exist.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 45 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•Age 18-45 years
•Subject is willing to comply with any applicable contraceptive requirements of the protocol and is:
•Non-pregnant, non-lactating female
•Females must be at least 90 days post partum or nulliparous.
•Female subjects must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test
•Satisfactory medical assessment
•Ability to provide information on family history of hypertension.
•Body Mass Index (BMI) between 18.5 and 30.0kg/m² inclusive.
•Ability to swallow all investigational products.

排除标准

•Current or recurrent disease (e.g., cardiovascular, renal, liver, gastrointestinal, malignancy or other conditions)
•Current or relevant previous history of physical or psychiatric illness.
•Significant illness.
•History of significant anxiety, tension, or agitation as assessed by the Investigator.
•History of or current diagnosis of glaucoma.
•History of a seizure disorder (other than infantile febrile seizures), any tic disorder or a current diagnosis and/or known family history of Tourette's Disorder.
•History of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, transient ischemic attack or stroke, or other serious cardiac problems.
•History of controlled or uncontrolled hypertension or a resting sitting systolic BP >139mmHg or diastolic BP >89mmHg.
•Known family history of sudden cardiac death or ventricular arrhythmia.
•Suicidal ideation or any lifetime history of suicidal behavior.
•Consumption of alcohol, Seville oranges, grapefruit, or any grapefruit containing products within 7 days of first dose of investigational product.
•Current use of any medication (including prescription, over the counter [OTC], herbal or homeopathic preparations or supplements) with the exception of the occasional dose of acetaminophen, or hormonal contraceptives.
•History of alcohol or other substance abuse within the last year.
•A positive screen for alcohol or drugs of abuse.
•Male subjects who consume more than 21 units of alcohol per week or 3 units per day. Female subjects who consume more than 14 units of alcohol per week or 2 units per day. [1 alcohol unit =1 beer = 1 wine (5oz) = 1 liquor (1.5oz) = 0.75oz alcohol]
•A positive human immunodeficiency virus (HIV) antibody screen, Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV) antibody screen.
•Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g. gum, patch). Ex-users must report that they have stopped using tobacco for at least 30 days prior to receiving the first dose of investigational product.
•Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches. (One caffeine unit is contained in the following items: one 6oz. cup of coffee, two 12oz. cans of cola, one 12oz. cup of tea, three 1oz. chocolate bars, or one 8oz. serving of an energy drink. Decaffeinated coffee, tea, or cola are not considered to contain caffeine).
•Donation of blood or blood products (e.g., plasma or platelets) within 60 days prior to receiving the first dose of investigational product.

研究组 & 干预措施

LDX (SPD489) + Venlafaxine XR (Effexor XR)

Experimental

干预措施: LDX + Venlafaxine XR (Drug)

Venlafaxine XR + LDX

Experimental

干预措施: Venlafaxine XR + LDX (Drug)